LAG3 and neoplasm: In recent years, novel checkpoint molecules such as lymphocyte-activation gene-3 (LAG-3), T-cell immunoglobulin 3 (TIM-3), and T-cell immunoglobulin and ITIM domain (TIGIT) have been widely and intensively studied in terms of the tumor immunosuppressive microenvironment, “T-cell depletion,” and corresponding targeted antibody therapy (13).